Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center
Launched by CEDARS-SINAI MEDICAL CENTER · Mar 20, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to see if hands-on nutritional demonstrations can be added to the Diabetes Prevention Program (DPP) for people who are at risk of developing diabetes. The goal is to find out if this kind of approach is practical and well-received by patients with prediabetes, which is a condition where blood sugar levels are higher than normal but not high enough to be classified as diabetes.
To participate in this study, individuals need to be at least 18 years old, have a body mass index (BMI) of 25 or higher (or 23 or higher if they are Asian), and meet specific blood sugar test results indicating prediabetes. Participants should also be enrolled in the DPP and have been identified by a healthcare provider as being at moderate to high risk for prediabetes in the past year. If eligible, participants can expect to engage in educational sessions focused on nutrition, which aim to help them make healthier choices and potentially prevent diabetes. This trial is currently not recruiting participants, but it represents an exciting opportunity to improve health education for those at risk.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18+ years old
- • BMI of 25 or higher (23 or higher if Asian)
- • Meet specific blood sugar test criteria indicating prediabetes, such as a fasting plasma glucose level between 110-125 mg/dL or an A1C level between 5.7-6.4%
- • Not be diagnosed with type 1 or type 2 diabetes
- • Moderate to high risk of having prediabetes or a known diagnosis of prediabetes by their medical provider in the last 12 months.
- • Eligible or enrolled in the Diabetes Prevention Program
- Exclusion Criteria:
- • Younger than 18 years of age
- • BMI of less than 25 or higher (or under 23 if Asian)
- • Does not meet specific blood sugar test criteria indicating prediabetes, such as a fasting plasma glucose level between 110-125 mg/dL or an A1C level between 5.7-6.4%
- • Currently diagnosed with type 1 or type 2 diabetes
- • Has not been diagnosed as moderate to high risk of having prediabetes or having a known diagnosis of prediabetes by their medical provider in the last 12 months.
About Cedars Sinai Medical Center
Cedars-Sinai Medical Center is a renowned nonprofit academic medical center located in Los Angeles, California, recognized for its commitment to patient care, research, and education. As a leading institution in clinical trials, Cedars-Sinai harnesses innovative approaches to advance medical knowledge and improve treatment outcomes across various specialties. With a multidisciplinary team of experts, state-of-the-art facilities, and a patient-centered approach, Cedars-Sinai actively contributes to the development of novel therapies and interventions, ensuring the highest standards of clinical research while prioritizing patient safety and ethical considerations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yelba Castellon-Lopez, MD
Principal Investigator
Cedars-Sinai Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported